Efficacy and Safety of Lumiracoxib in Patients With Knee Osteoarthritis (OA).

Completed · Phase 3

Conditions studied: Osteoarthritis, Knee

In brief

This study will investigate the efficacy and safety of lumiracoxib in patients with primary knee osteoarthritis (OA).

Key facts

Study ID

NCT00366938

Run by

Novartis

People needed

1464

Starts

2003-09-01

Last updated by the study team

2012-05-21

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Primary osteoarthritis of knee (confirmed by American College of Rheumatology [ACR] criteria).
• Requirement of regular non-steroidal anti-inflammatory drug (NSAID) therapy.

You may not qualify if…

• Evidence of active gastrointestinal ulceration within 12 months prior to the screening visit or history of active gastrointestinal bleeding within the previous 5 years.
• Known hypersensitivity to analgesics, antipyretics, or NSAIDS (including celecoxib).
• Other protocol-defined inclusion/exclusion criteria may apply.

Where it is running

• Novartis Pharmaceuticals Corporation — East Hanover, New Jersey, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.